MaxCyte Investor Presentation Deck

MaxCyte-Enabled Active Clinical Trials. Clinical Phase: Phase 1 Phase 1/2 Pivotal Cell Approach: Allogeneic Autologous As of March 2023/ Includes Commercial and Academic Clinical Trials Program received IND clearance but is not yet listed on clinicaltrials.gov CBO10 (Caribou) CAR-T Azer-Cel (Precision) CD34+/HSCS Trem-cel (Vor) CD34+/HSCS 16 Exa-cel: B-thal (Vertex) EDIT301: B-thal (Editas) Exa-cel: SCD (Vertex) M MaxCyte EDIT301: SCD (Editas) M MaxCyte Other Cell Types/ Approaches APN401 (Invios) © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation